MAPT and Alzheimer disease: The finding that treatment-related decreases in NDEV total tau levels were associated with improvements in cognitive performance as assessed by ADAS-cog+highlights the relevance of this biomarker for cognition in AD and supports the possibility that Cerebrolysin® and combination therapy effects on tau expression and cognition are mediated by direct actions on the brain.